Alpha Tau Medical

Historical price data

Alpha Tau Medical is developing a breakthrough alpha-radiation therapy for solid tumors, with its core Alpha DaRT technology originating from Tel Aviv University in 2003. The company is now in clinical execution mode, with multiple active, recruiting trials across seven cancer types at leading global cancer centers. Its strategic focus is on demonstrating efficacy and safety across a diverse oncology portfolio to address significant unmet needs in both accessible and hard-to-treat tumors.

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy): An intratumoral radiotherapy platform using Radium-224-impregnated sources that release short-range, high-energy alpha particles to ablate solid tumors while sparing healthy tissue.

1 drug in pipeline

Total raised: $109M

Alpha Tau competes with traditional external beam radiotherapy (Varian, Elekta), beta-emitting brachytherapy (Boston Scientific), and systemic targeted radiotherapies (Novartis). Its differentiation is the localized delivery of highly potent alpha radiation, aiming for superior tumor kill with minimal off-target effects compared to these alternatives.